Exact Mass: 429.1544602
Exact Mass Matches: 429.1544602
Found 58 metabolites which its exact mass value is equals to given mass value 429.1544602
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Pizotifen malate
C23H27NO5S (429.1609852000001)
Pizotifen malate (Pizotyline malate) is a potent 5-HT2 receptor antagonist, with a high affinity for 5-HT1C binding site.
14N-Ac-9-[(2-Amino-2-carboxyethyl)thio]-10-hydroxy-3,5,7-tetradecatrienedioic acid
14-carboxy-15,16,17,18,19,20-hexanor-N-acetyl-leukotriene E4
Amicycline
C784 - Protein Synthesis Inhibitor > C1595 - Tetracycline Antibiotic C254 - Anti-Infective Agent > C258 - Antibiotic
7-(Benzyloxy)-4-(4-Fluoro-2-Methyl-1h-Indol-5-Yloxy)-6-Methoxyquinazoline
C25H20FN3O3 (429.14886220000005)
2-(((1-(TERT-BUTOXY)-2-METHYL-1-OXOPROPAN-2-YL)OXY)IMINO)-2-(2-((TERT-BUTOXYCARBONYL)AMINO)THIAZOL-4-YL)ACETIC ACID
2-(2-ETHOXY-1-BUTENYL)-5-PHENYL-3-(3-SULFOBUTYL)BENZOXAZOLIUM INNER SALT
C23H27NO5S (429.1609852000001)
Erlotinib hydrochloride
C22H24ClN3O4 (429.14552540000005)
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents
ethyl 1,4-dihydro-7-[(S,S)-3-methoxy-4-methylamino-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylate
C20H23N5O4S (429.14706780000006)
Thioxanthene-2-sulfonamide, N,N-dimethyl-9-(3-(1-piperazinyl)propylidene)-, (E)-
[4-(4-Acetylamino-phenyl)-3,5-dioxo-4-aza-tricyclo[5.2.2.0 2,6]undec-1-ylcarbamoyloxy]-acetic acid
Ipratropium bromide hydrate
C20H32BrNO4 (429.15145720000004)
D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents
N-phenyl-5-(7-piperidin-4-yloxyisoquinolin-6-yl)thiophene-2-carboxamide
Tarceva
C22H24ClN3O4 (429.14552540000005)
D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents
2-[[4-(4-fluorophenyl)-5-[(1-methyl-2-pyrrolyl)methyl]-1,2,4-triazol-3-yl]thio]-N-(2-oxolanylmethyl)acetamide
N-(2-ethylphenyl)-2-[[2-(4-methoxyphenyl)-4-oxo-1-benzopyran-6-yl]oxy]acetamide
C26H23NO5 (429.15761480000003)
{[(1r,7r)-4-(4-Acetamidophenyl)-3,5-dioxo-4-azatricyclo[5.2.2.0(2,6)]undec-1-yl]carbamoyloxy}acetic acid
2-[[(4-ethoxyphenyl)-oxomethyl]amino]acetic acid [2-(9H-fluoren-3-yl)-2-oxoethyl] ester
C26H23NO5 (429.15761480000003)
N-(18-Phenyl-11-oxa-13,15-diazatetracyclo[8.8.0.02,7.012,17]octadeca-1(10),2,4,6,8,12,14,16-octaen-16-yl)benzamide
2-[(3R,6aR,8R,10aR)-3-hydroxy-1-(2-methoxyphenyl)sulfonyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester
3-[4-[(1R,5S)-3-(2-methylphenyl)sulfonyl-3,6-diazabicyclo[3.1.1]heptan-7-yl]phenyl]benzonitrile
4-[4-[(1S,5R)-3-(phenylmethyl)sulfonyl-3,6-diazabicyclo[3.1.1]heptan-7-yl]phenyl]benzonitrile
4-[4-[(1R,5S)-3-(2-methylphenyl)sulfonyl-3,6-diazabicyclo[3.1.1]heptan-7-yl]phenyl]benzonitrile
methyl 2-[(3R,6aS,8R,10aS)-3-hydroxy-1-(2-methoxyphenyl)sulfonyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetate
2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(2-methoxyphenyl)sulfonyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester
methyl 2-[(3S,6aS,8R,10aS)-3-hydroxy-1-(2-methoxyphenyl)sulfonyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetate
2-[(3S,6aR,8R,10aR)-3-hydroxy-1-(2-methoxyphenyl)sulfonyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester
2-[(2R,4aR,12aR)-5-methyl-8-[[(5-methyl-3-isoxazolyl)-oxomethyl]amino]-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]acetic acid
2-[(3R,6aR,8S,10aR)-3-hydroxy-1-(2-methoxyphenyl)sulfonyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester
2-[(3S,6aS,8S,10aS)-3-hydroxy-1-(2-methoxyphenyl)sulfonyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester
2-[(E)-(2-oxo-1H-indol-3-ylidene)amino]-N-(2-phenylethyl)-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide
N-[4-[[5-[3-(2-aminoethyl)-1H-indol-5-yl]-1,2,4-oxadiazol-3-yl]methyl]phenyl]methanesulfonamide;hydrate
C20H23N5O4S (429.14706780000006)
Ipratropium (bromide hydrate)
C20H32BrNO4 (429.15145720000004)
Ipratropium bromide (Sch 1000) hydrate is a muscarinic receptor antagonist, with IC50s of 2.9 nM, 2 nM, and 1.7 nM for M1, M2, and M3 receptors, respectively. Ipratropium bromide hydrate relaxes smooth muscle, can be used in the research for COPD (chronic obstructive pulmonary disease) and asthma[1][2][3][4][5].
3-nitropropyl allolactoside
{"Ingredient_id": "HBIN008981","Ingredient_name": "3-nitropropyl allolactoside","Alias": "NA","Ingredient_formula": "C15H27NO13","Ingredient_Smile": "NA","Ingredient_weight": "429.377","OB_score": "NA","CAS_id": "117845-08-O","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "8027","PubChem_id": "NA","DrugBank_id": "NA"}
2-(cyanomethylidene)-5,6-dihydroxy-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}cyclohexyl 3-methylbut-2-enoate
C19H27NO10 (429.16348819999996)
2,12,16,19,29-pentaazaoctacyclo[15.13.1.1¹⁸,²⁶.0¹,¹⁰.0³,⁸.0¹³,³¹.0²⁰,²⁵.0³⁰,³²]dotriaconta-3,5,7,13(31),16,18,20(25),21,23,26(32),27,29-dodecaen-9-one
C27H19N5O (429.15895240000003)
(1s,10s)-2,12,16,19,29-pentaazaoctacyclo[15.13.1.1¹⁸,²².0¹,¹⁰.0³,⁸.0¹³,³¹.0²³,²⁸.0³⁰,³²]dotriaconta-3,5,7,13(31),16,18,20,22(32),23(28),24,26,29-dodecaen-9-one
C27H19N5O (429.15895240000003)
3-(cyanomethylidene)-2,6-dihydroxy-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}cyclohexyl 3-methylbut-2-enoate
C19H27NO10 (429.16348819999996)
4-(cyanomethylidene)-2,3-dihydroxy-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}cyclohexyl 3-methylbut-2-enoate
C19H27NO10 (429.16348819999996)
(1s,2e,3r,5s,6s)-2-(cyanomethylidene)-5,6-dihydroxy-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}cyclohexyl 3-methylbut-2-enoate
C19H27NO10 (429.16348819999996)
(9s,12s,15s)-9-amino-4,10,13-trihydroxy-12-(hydroxymethyl)-2-oxa-11,14-diazatricyclo[15.2.2.1³,⁷]docosa-1(19),3(22),4,6,10,13,17,20-octaene-15-carboxylic acid
(1s,2r,3s,4z,5r)-4-(cyanomethylidene)-2,3-dihydroxy-5-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}cyclohexyl 3-methylbut-2-enoate
C19H27NO10 (429.16348819999996)
(1s,2s,3z,4r,6s)-3-(cyanomethylidene)-2,6-dihydroxy-4-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}cyclohexyl 3-methylbut-2-enoate
C19H27NO10 (429.16348819999996)